| Literature DB >> 34437419 |
Hong-Yan Zhao1, Yan Sun1, Yu Du2,3,4, Jia-Qi Li4, Jin-Geng Lv2,3, Yan-Fu Qu4, Long-Hui Lin1, Chi-Xian Lin2,3, Xiang Ji3,4,5, Jian-Fang Gao1.
Abstract
Given that the venom system in sea snakes has a role in enhancing their secondary adaption to the marine environment, it follows that elucidating the diversity and function of venom toxins will help to understand the adaptive radiation of sea snakes. We performed proteomic and de novo NGS analyses to explore the diversity of venom toxins in the annulated sea snake (Hydrophis cyanocinctus) and estimated the adaptive molecular evolution of the toxin-coding unigenes and the toxicity of the major components. We found three-finger toxins (3-FTxs), phospholipase A2 (PLA2) and cysteine-rich secretory protein (CRISP) in the venom proteome and 59 toxin-coding unigenes belonging to 24 protein families in the venom-gland transcriptome; 3-FTx and PLA2 were the most abundant families. Nearly half of the toxin-coding unigenes had undergone positive selection. The short- (i.p. 0.09 μg/g) and long-chain neurotoxin (i.p. 0.14 μg/g) presented fairly high toxicity, whereas both basic and acidic PLA2s expressed low toxicity. The toxicity of H. cyanocinctus venom was largely determined by the 3-FTxs. Our data show the venom is used by H. cyanocinctus as a biochemically simple but genetically complex weapon and venom evolution in H. cyanocinctus is presumably driven by natural selection to deal with fast-moving prey and enemies in the marine environment.Entities:
Keywords: Hydrophis cyanocinctus; diversity; omics; positive selection; venom toxin
Mesh:
Substances:
Year: 2021 PMID: 34437419 PMCID: PMC8402435 DOI: 10.3390/toxins13080548
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1The venom proteomic profile of H. cyanocinctus. (A) Protein elution profile of venom. The proteins were separated by a C18 column as described in the Materials and Methods section. Fractions were collected and analysed by SDS-PAGE under reduced conditions. Protein bands were excised, tryptic-digested and analysed by nESI-MS/MS for their assignment to known protein families. (B) Relative abundance of venom toxin families. 3-FTx, three-finger toxin; LNX, long-chain α-neurotoxin; SNX, short-chain α-neurotoxin; PLA2, phospholipase A2; CRISP, cysteine-rich secretory protein. The details are listed in Table 1.
Assignment of the chromatographic fractions and electrophoretic bands from H. cyanocinctus venom to protein families.
| Peak | % | MW | Peptide Ion | MS/MS-Derived Sequence | Protein Family/Species/Accession/Transcript ID | |
|---|---|---|---|---|---|---|
|
| ||||||
| 1 | 19.19 | 9.3 | 775.3 | 2 | TTTNCAESSCYKK | 3-FTx (SNX); |
| 2 | 3.74 | 7.3 | 537.3 | 3 | XEFGCAATCPTVBR | 3-FTx (LNX); |
| 3 | 0.27 | 7.3 | 537.3 | 3 | XEFGCAATCPTVBR | 3-FTx (LNX); |
| 4 | 0.22 | 7.3 | 805.4 | 2 | XEFGCAATCPTVBR | 3-FTx (LNX); |
| 5 | 0.23 | 7.4 | 805.4 | 2 | XEFGCAATCPTVBR | 3-FTx (LNX); |
| 6 | 1.48 | 7.0 | 537.3 | 3 | XEFGCAATCPTVBR | 3-FTx (LNX); |
| 7 | 6.17 | 7.3 | 531.9 | 3 | RXEMGCAATCPTVB | 3-FTx (LNX); |
| 8 | 5.85 | 7.3 | 588.3 | 2 | GBVXEXGCTAB | 3-FTx (LNX); |
| 9 | 17.79 | 7.6 | 588.3 | 2 | GBVXEXGCTAB | 3-FTx (LNX); |
| 10 | 1.22 | 17.2 | 591.3 | 3 | BVCDCDVAAAECFAR | Basic PLA2; |
| 11.8 | 591.3 | 3 | BVCDCDVAAAECFAR | Basic PLA2; | ||
| 0.77 | 7.3 | 588.3 | 2 | GBVXEXGCTAB | 3-FTx (LNX); | |
| 11 | 6.19 | 11.7 | 618.8 | 2 | BVCDCDVAAAB | Basic PLA2; |
| 7.3 | 591.3 | 3 | BVCDCDVAAAECFAR | Basic PLA2; | ||
| 12 | 3.35 | 11.7 | 591.3 | 3 | BVCDCDVAAAECFAR | Basic PLA2; |
| 0.49 | 7.4 | 588.3 | 2 | GBVXEXGCTAB | 3-FTx (LNX); | |
| 13 | 1.51 | 12.0 | 822.3 | 2 | VCDCDVAAAECFAR | Basic PLA2; |
| 0.80 | 7.3 | 588.3 | 2 | GBVXEXGCTAB | 3-FTx (LNX); | |
| 14 | 0.29 | 12.0 | 591.3 | 3 | BVCDCDVAAAECFAR | Basic PLA2; |
| 1.10 | 7.7 | 773.4 | 3 | THPYBPETCPPGBNXCYBB | 3-FTx (LNX); | |
| 15 | 2.05 | 12.3 | 455.2 | 2 | TAAXCFAR | Acidic PLA2; |
| 16 | 7.15 | 11.4 | 455.2 | 2 | TAAXCFAR | Acidic PLA2; |
| 17 | 10.02 | 10.4 | 455.8 | 2 | XTXYSWB | Basic PLA2; |
| 18 | 3.21 | 10.7 | 644.3 | 3 | DNNDECBAFXCNCDR | Acidic PLA2; |
| 19 | 5.11 | 11.4 | 455.3 | 2 | TAAXCFAR | Acidic PLA2; |
| 20 | 1.80 | 23.6 | 448.2 | 3 | CTFAHSPEHTR | CRISP; |
X: Leu/Ile; B: Lys/Gln. 3-FTx, three-finger toxin; PLA2, phospholipase A2; CRISP, cysteine-rich secretory protein; LNX, long-chain α-neurotoxin; SNX, short-chain α-neurotoxin. Transcripts are listed in the Supplementary Materials, Table S1.
The median lethal doses (LD50) of H. cyanocinctus venom and the major fractions separated by RP-HPLC.
| Fraction | Toxin | Intraperitoneal LD50 (μg/g) * |
|---|---|---|
| - | Crude venom | 0.26 (0.23–0.30) |
| - | Whole venom protein ** | 0.16 (0.12–0.20) |
| 1 | Short neurotoxin | 0.09 (0.07–0.12) |
| 7 | Long neurotoxin | 0.14 (0.09–0.21) |
| 11 | Basic PLA2 | >0.6 |
| 18 | Acidic PLA2 | >2.0 |
*: values in parentheses are 95% confidence limits. **: Whole venom protein was defined as the protein in crude venom and quantified by the crude venom after determination of the protein concentration.
Figure 2The venom-gland transcriptomic profile of H. cyanocinctus. The details are listed in the Supplementary Materials, Tables S1 and S2.
Figure 3Comparison of the overall venom-gland transcriptomic profiles of three sea snakes: (A) current study; (B–D) cited and rearranged from Zhao et al. [24], Tan et al. [29] and Durban et al. [27], respectively. NC, non-conventional neurotoxin; SVSP, snake venom serine proteinase; AchE, acetylcholinesterase. Relative abundances less than 0.01% are not indicated in the toxin families.
Figure 4Correlation between mRNA and protein abundances of individual transcripts for each toxin family. N, number of toxin transcripts; ρ, Spearman’s rank correlation coefficient; R, Pearson’s correlation coefficient; R, determination coefficient.
Summary of codeml tests for positive selection of toxins from venom-gland transcriptome in H. cyanocinctus.
| Toxins (No.) | M1: Nearly Neutral | −ln | M2: Positive Selection | −ln | M0: | Δ a | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3-FTx (1, 2, 3) | 0.56 | 0.44 | 608.01 | 0.45 | 0.27 | 0.28 | 588.51 | 2.79 | 39.00 | 3.40 × 10−9 * | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 9.84 | ||||||||
| 5NT (1, 2) | 0.60 | 0.40 | 3831.74 | 0.90 | 0.00 | 0.10 | 3829.66 | 0.40 | 4.16 | 0.12 | ||
| 0.00 | 1.00 | 0.21 | 1.00 | 2.57 | ||||||||
| AP (1) | 0.63 | 0.37 | 5224.95 | 0.93 | 0.00 | 0.07 | 5221.58 | 0.40 | 6.74 | 0.03 | ||
| 0.00 | 1.00 | 0.22 | 1.00 | 3.95 | ||||||||
| CRISP (1, 2) | 0.47 | 0.53 | 2499.04 | 0.40 | 0.39 | 0.22 | 2458.11 | 1.38 | 81.87 | 0.00* | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 4.74 | ||||||||
| CTL (1) | 0.56 | 0.44 | 1046.59 | 0.82 | 0.00 | 0.18 | 1045.29 | 0.52 | 2.60 | 0.27 | ||
| 0.00 | 1.00 | 0.19 | 1.00 | 2.49 | ||||||||
| CTL (2) | 0.60 | 0.40 | 1177.31 | 0.80 | 0.07 | 0.13 | 1172.58 | 0.56 | 9.46 | 8.83 × 10−3 | ||
| 0.06 | 1.00 | 0.22 | 1.00 | 3.07 | ||||||||
| CTL (3) | 0.55 | 0.45 | 1186.50 | 0.60 | 0.00 | 0.40 | 1184.23 | 0.62 | 4.55 | 0.10 | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 1.65 | ||||||||
| Cystatin (1) | 0.29 | 0.71 | 979.80 | 0.96 | 0.00 | 0.04 | 969.73 | 1.15 | 20.13 | 4.25 × 10−5 * | ||
| 0.04 | 1.00 | 0.84 | 1.00 | 11.02 | ||||||||
| DPP IV | 0.64 | 0.36 | 4740.05 | 0.83 | 0.11 | 0.06 | 4730.48 | 0.43 | 19.12 | 7.05 × 10−5 * | ||
| 0.00 | 1.00 | 0.15 | 1.00 | 3.82 | ||||||||
| HA | 0.45 | 0.55 | 2976.76 | 0.52 | 0.00 | 0.48 | 2975.36 | 0.62 | 2.81 | 0.25 | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 1.38 | ||||||||
| Kunitz (1) | 0.82 | 0.18 | 1502.79 | 0.82 | 0.11 | 0.08 | 1502.79 | 0.33 | 0.00 | 1.00 | ||
| 0.21 | 1.00 | 0.21 | 1.00 | 1.00 | ||||||||
| Kunitz (2) | 0.44 | 0.56 | 944.01 | 0.18 | 0.44 | 0.38 | 916.66 | 3.14 | 54.70 | 1.32 × 10−12 * | ||
| 0.05 | 1.00 | 0.00 | 1.00 | 7.95 | ||||||||
| LAAO | 0.44 | 0.56 | 6029.83 | 0.39 | 0.43 | 0.17 | 5970.56 | 1.03 | 118.53 | 0.00* | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 4.00 | ||||||||
| NGF (1, 2) | 0.51 | 0.49 | 1366.53 | 0.39 | 0.46 | 0.15 | 1342.54 | 1.30 | 47.98 | 3.81 × 10−11 * | ||
| 0.07 | 1.00 | 0.13 | 1.00 | 5.87 | ||||||||
| PLA2 (1) | 0.47 | 0.53 | 1913.94 | 0.41 | 0.21 | 0.38 | 1877.93 | 1.57 | 72.01 | 2.22 × 10−16 * | ||
| 0.01 | 1.00 | 0.00 | 1.00 | 4.16 | ||||||||
| PLA2 (2) | 0.45 | 0.55 | 808.89 | 0.68 | 0.00 | 0.32 | 796.33 | 1.95 | 25.12 | 3.51 × 10−6 * | ||
| 0.00 | 1.00 | 0.15 | 1.00 | 8.00 | ||||||||
| PLA2 inhibitor (1) | 0.48 | 0.52 | 1900.98 | 0.50 | 0.00 | 0.50 | 1900.96 | 0.50 | 0.04 | 0.98 | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 1.07 | ||||||||
| PLB | 0.56 | 0.44 | 3750.75 | 0.53 | 0.45 | 0.02 | 3742.03 | 0.54 | 17.44 | 1.63 × 10−4 * | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 6.82 | ||||||||
| QC | 0.78 | 0.22 | 2194.10 | 0.79 | 0.00 | 0.21 | 2194.09 | 0.21 | 0.01 | 1.00 | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 1.05 | ||||||||
| SVMP (1) | 0.48 | 0.52 | 8066.12 | 0.35 | 0.46 | 0.19 | 7910.53 | 1.38 | 311.17 | 0.00 * | ||
| 0.04 | 1.00 | 0.00 | 1.00 | 5.06 | ||||||||
| VEGF | 0.31 | 0.69 | 1101.80 | 0.87 | 0.00 | 0.13 | 1101.01 | 0.82 | 1.58 | 0.45 | ||
| 0.00 | 1.00 | 0.49 | 1.00 | 3.83 | ||||||||
| VF | 0.53 | 0.47 | 13764.79 | 0.51 | 0.46 | 0.04 | 13,726.91 | 0.61 | 75.76 | 0.00 * | ||
| 0.00 | 1.00 | 0.00 | 1.00 | 4.96 | ||||||||
*, significance at the 5% level after Bonferroni correction; a, negative twice the difference in lnL between M1 and M2; b, p-value before correction.